Evidence map›Paper›PMID 40727552›Full record

ReviewCurrent pulmonology reports2025

The Potential Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor Agonists in Obstructive Sleep Apnea and Obesity.

Charlotte C Ellberg, Hannah Schwartz, Annika Witt, Karen C McCowen, Ana Lucia Fuentes, Atul Malhotra

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current pulmonology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Charlotte C EllbergDepartment of Medicine, University of California, San Diego, La Jolla, CA USA.
Hannah SchwartzDepartment of Medicine, Weill Cornell Medicine, New York, NY USA.
Annika WittBrown University, Providence, RI USA.
Karen C McCowenDivision of Endocrinology, University of California, San Diego, La Jolla, CA USA.
Ana Lucia FuentesDivision of Pulmonary, Critical Care, Sleep Medicine and Physiology, University of California, Gilman Drive, San Diego, La Jolla, CA 9500 USA.
Atul MalhotraDivision of Pulmonary, Critical Care, Sleep Medicine and Physiology, University of California, Gilman Drive, San Diego, La Jolla, CA 9500 USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose of Review: Strong associations exist between obstructive sleep apnea (OSA) and obesity. Prior studies have demonstrated that weight reduction in people with OSA and obesity improves severity of OSA. Until recently, there were no approved pharmacotherapies for OSA. We aim to review recent literature on GLP-1 receptor agonists and GIP agonists and their potential role in the management of OSA. Recent Findings: Novel pharmacotherapies developed to target obesity include glucagon-like peptide-1 (GLP-1) receptor agonists and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists. These therapies have proven to be helpful in many comorbid conditions, with published studies suggesting a benefit in OSA. Summary: GLP-1 receptor agonists and GIP agonists are emerging potential therapies for OSA and associated cardiometabolic risk.

Indexed as

CardiometabolicGIP receptor agonistGLP-1 receptor agonistObesity, lungWeight loss

Identifiers

PMID40727552
PMCPMC12289732

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.